Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of DS-5141b in Duchenne Muscular Dystrophy
NCT04433234Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Jan 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of renadirsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of Adverse Events at 2 years, 6-Minute Walk Test at 24 months and 8 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
renadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04433234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433234.